AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 219
(A-19)

Introduced by: Oklahoma

Subject: Medical Marijuana License Safety

Referred to: Reference Committee B
(Charles Rothberg, MD, Chair)

Whereas, Our American Medical Association supports the voluntary use of state-based prescription drug monitoring programs (PDMP) when clinically appropriate; and

Whereas, Our AMA encourages states to implement modernized PDMPs that are seamlessly integrated into the physician's normal workflow, and provide clinically relevant, reliable information at the point of care within the safeguards applicable to protected health information; and

Whereas, Our AMA encourages all states to determine how to use a PDMP to enhance treatment for substance use disorder and pain management; and

Whereas, Our AMA encourages states to share access to PDMP data across state lines; and

Whereas, By 2018, 33 states, the District of Columbia, Guam, and Puerto Rico, have passed legislation to legalize medical marijuana, including Oklahoma; and

Whereas, In 2018, Oklahoma State Question 788, Medical Marijuana Legalization Initiative, became law of the land and lacks adequate patient safeguards in multiple areas; and

Whereas, Patient safety standards have not been implemented in all state legislation that have legalized medical marijuana; and

Whereas, Physicians need accurate and reliable information to give high-level care to their patients; therefore be it

RESOLVED, That our American Medical Association draft model state legislation to amend states’ prescription drug monitoring programs to include a medical marijuana license registry.

Fiscal Note: Not yet determined

Received: 04/15/19
RELEVANT AMA POLICY

Development and Promotion of Single National Prescription Drug Monitoring Program H-95.939
Our American Medical Association (1) supports the voluntary use of state-based prescription drug monitoring programs (PDMP) when clinically appropriate; (2) encourages states to implement modernized PDMPs that are seamlessly integrated into the physician's normal workflow, and provide clinically relevant, reliable information at the point of care; (3) supports the ability of physicians to designate a delegate to perform a check of the PDMP, where allowed by state law; (4) encourage states to foster increased PDMP use through a seamless registration process; (5) encourages all states to determine how to use a PDMP to enhance treatment for substance use disorder and pain management; (6) encourages states to share access to PDMP data across state lines, within the safeguards applicable to protected health information; and (7) encourages state PDMPs to adopt uniform data standards to facilitate the sharing of information across state lines.
Citation: BOT Rep. 12, A-15; Reaffirmed: BOT Rep. 5, I-15; Reaffirmation A-16